Expanded Hemodialysis Therapy Ameliorates Uremia-Induced Systemic Microinflammation and Endothelial Dysfunction by Modulating VEGF, TNF-α and AP-1 Signaling.
Aged
Biomarkers
Computational Biology
Cytokines
/ blood
Disease Susceptibility
Endothelial Cells
/ metabolism
Endothelium, Vascular
/ metabolism
Female
Humans
Inflammation
/ diagnosis
Male
Middle Aged
Proteomics
/ methods
Renal Dialysis
/ methods
Signal Transduction
Transcription Factor AP-1
/ metabolism
Tumor Necrosis Factor-alpha
/ metabolism
Uremia
/ complications
Vascular Endothelial Growth Factor A
/ metabolism
cardiovascular disease
chronic kidney disease
end-stage renal disease
endothelial cell (dys)function
expanded hemodialysis therapy
tumor necrosis factor alpha (TNF-alpha)
uremic toxins / systemic microinflammation
vascular endothelial growth factor (VEGF)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
09
2021
accepted:
20
10
2021
entrez:
3
12
2021
pubmed:
4
12
2021
medline:
11
2
2022
Statut:
epublish
Résumé
Systemic chronic microinflammation and altered cytokine signaling, with adjunct cardiovascular disease (CVD), endothelial maladaptation and dysfunction is common in dialysis patients suffering from end-stage renal disease and associated with increased morbidity and mortality. New hemodialysis filters might offer improvements. We here studied the impact of novel improved molecular cut-off hemodialysis filters on systemic microinflammation, uremia and endothelial dysfunction. Human endothelial cells (ECs) were incubated with uremic serum obtained from patients treated with two different hemodialysis regimens in the Permeability Enhancement to Reduce Chronic Inflammation (PERCI-II) crossover clinical trial, comparing High-Flux (HF) and Medium Cut-Off (MCO) membranes, and then assessed for their vascular endothelial growth factor (VEGF) production and angiogenesis. Compared to HF membranes, dialysis with MCO membranes lead to a reduction in proinflammatory mediators and reduced endothelial VEGF production and angiogenesis. Cytokine multiplex screening identified tumor necrosis factor (TNF) superfamily members as promising targets. The influence of TNF-α and its soluble receptors (sTNF-R1 and sTNF-R2) on endothelial VEGF promoter activation, protein release, and the involved signaling pathways was analyzed, revealing that this detrimental signaling was indeed induced by TNF-α and mediated by AP-1/c-FOS signaling. In conclusion, uremic toxins, in particular TNF-signaling, promote endothelial maladaptation, VEGF expression and aberrant angiogenesis, which can be positively modulated by dialysis with novel MCO membranes. Systemic microinflammation, altered cytokine signaling, cardiovascular disease, and endothelial maladaptation/dysfunction are common clinical complications in dialysis patients suffering from end-stage renal disease. We studied the impact of novel improved medium-cut-off hemodialysis filters on uremia and endothelial dysfunction. We can show that uremic toxins, especially TNF-signaling, promote endothelial maladaptation, VEGF expression and aberrant angiogenesis, which can be positively modulated by dialysis with novel improved medium-cut-off membranes.
Identifiants
pubmed: 34858433
doi: 10.3389/fimmu.2021.774052
pmc: PMC8632537
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
Transcription Factor AP-1
0
Tumor Necrosis Factor-alpha
0
Vascular Endothelial Growth Factor A
0
Banques de données
ClinicalTrials.gov
['NCT02084381']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
774052Informations de copyright
Copyright © 2021 Catar, Moll, Kamhieh-Milz, Luecht, Chen, Zhao, Ernst, Willy, Girndt, Fiedler, Witowski, Morawietz, Ringdén, Dragun, Eckardt, Schindler and Zickler.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Am J Cardiol. 2001 Mar 15;87(6):805-7, A9
pubmed: 11249912
Science. 1997 Jul 4;277(5322):55-60
pubmed: 9204896
Nephrol Dial Transplant. 2018 Oct 1;33(suppl_3):iii35-iii40
pubmed: 30281126
Stem Cells. 2018 Feb;36(2):161-171
pubmed: 29226477
Nephrol Dial Transplant. 2018 Apr 1;33(4):543-548
pubmed: 29420799
Am J Nephrol. 2012;36(3):261-70
pubmed: 22965073
Kidney Int. 2013 Dec;84(6):1119-28
pubmed: 23760290
Circ Res. 2016 Feb 19;118(4):620-36
pubmed: 26892962
Trends Mol Med. 2019 Feb;25(2):149-163
pubmed: 30711482
Nephrol Dial Transplant. 2016 Oct;31(10):1706-12
pubmed: 27445317
J Hypertens. 2005 Jun;23(6):1191-202
pubmed: 15894895
Cardiovasc Res. 2020 Aug 1;116(10):e122-e125
pubmed: 32678443
Nephrol Dial Transplant. 2008 Mar;23(3):783-5
pubmed: 18178601
Toxins (Basel). 2018 May 29;10(6):
pubmed: 29844272
Nephrol Dial Transplant. 2013 Sep;28(9):2356-63
pubmed: 23828162
J Immunol. 1995 Jan 15;154(2):882-92
pubmed: 7814891
N Engl J Med. 2004 Sep 23;351(13):1296-305
pubmed: 15385656
J Virol. 2011 Aug;85(15):7766-74
pubmed: 21632768
Clin J Am Soc Nephrol. 2010 Feb;5(2):227-34
pubmed: 20056757
PLoS One. 2017 Jan 13;12(1):e0169024
pubmed: 28085888
Artif Organs. 2017 Sep;41(9):803-809
pubmed: 28524237
BMC Nephrol. 2018 May 21;19(1):117
pubmed: 29783932
Nat Rev Nephrol. 2021 Jan;17(1):46-64
pubmed: 33077917
Stem Cell Res Ther. 2020 Aug 12;11(1):352
pubmed: 32787906
Nat Rev Nephrol. 2020 Dec;16(12):747-764
pubmed: 33060844
Lancet. 2013 Jul 27;382(9889):353-62
pubmed: 23727164
J Cell Sci. 2015 Jun 15;128(12):2236-48
pubmed: 25956888
Eur Heart J. 2020 Sep 1;41(32):3038-3044
pubmed: 32882706
Eur J Clin Invest. 2015 Dec;45(12):1333-40
pubmed: 26519693
Kidney Int. 2005 Apr;67(4):1216-33
pubmed: 15780075
Adv Sci (Weinh). 2021 Feb 08;8(7):2003119
pubmed: 33854887
J Am Soc Nephrol. 2017 Apr;28(4):1188-1199
pubmed: 27837150
Acta Haematol. 2001;106(4):148-56
pubmed: 11815711
Gene Ther. 2012 Jun;19(6):622-9
pubmed: 22378343
Clin Nephrol. 2000 Feb;53(2):115-23
pubmed: 10711413
Front Immunol. 2019 Nov 08;10:2474
pubmed: 31781089
Diabetes Metab Syndr. 2017 Nov;11 Suppl 1:S61-S64
pubmed: 28040466
BMJ. 2020 Oct 21;371:m3734
pubmed: 33087345
Kidney Int. 2009 Aug;76(3):262-76
pubmed: 19436333
Stem Cells. 2012 Jul;30(7):1565-74
pubmed: 22522999
Nephrol Dial Transplant. 2017 Jan 1;32(1):165-172
pubmed: 27587605
Lancet. 2013 Jul 13;382(9887):158-69
pubmed: 23727165
Stem Cells. 2014 Sep;32(9):2430-42
pubmed: 24805247
Hypertension. 2001 Oct;38(4):938-42
pubmed: 11641313
Nat Rev Nephrol. 2020 Jun;16(6):308-310
pubmed: 32273593
J Am Soc Nephrol. 2013 Feb;24(2):179-89
pubmed: 23138485
Nat Commun. 2016 Feb 04;7:10623
pubmed: 26842907
Stem Cells Dev. 2015 Oct 1;24(19):2269-79
pubmed: 26192403
Oncogene. 1997 Aug 7;15(6):669-76
pubmed: 9264407
Nephrol Dial Transplant. 2018 Apr 1;33(4):574-585
pubmed: 29228352
Nephrol Dial Transplant. 2018 Oct 1;33(suppl_3):iii22-iii27
pubmed: 30281130
JAMA Surg. 2016 Nov 1;151(11):1070-1077
pubmed: 27551978
Nat Rev Nephrol. 2018 Jun;14(6):394-410
pubmed: 29730670
Cell Commun Signal. 2021 Jan 4;19(1):1
pubmed: 33397378
Nephrol Dial Transplant. 2018 Oct 1;33(suppl_3):iii41-iii47
pubmed: 30281134
PLoS One. 2015 Nov 20;10(11):e0143079
pubmed: 26587841
Proc Natl Acad Sci U S A. 2019 Oct 1;116(40):20210-20217
pubmed: 31527268
Pharmacol Rep. 2010 Mar-Apr;62(2):311-8
pubmed: 20508287
PLoS One. 2011;6(7):e21703
pubmed: 21747949
PLoS One. 2014 Jan 13;9(1):e85040
pubmed: 24454787
Cells. 2021 Apr 15;10(4):
pubmed: 33920990
Front Immunol. 2020 Dec 17;11:607030
pubmed: 33391276
Circulation. 2003 Oct 28;108(17):2154-69
pubmed: 14581387